August 2015: SMC decisions
The Scottish Medicines Consortium (SMC) has accepted the following medicines for NHS Scotland for particular indications: darunavir cobicistat (Rezolsta; Janssen-Cilag); palonosetron (Aloxi; Chugai); tiotropium (Spiriva Respimat; Boehringer Ingelheim). Tedizolid phosphate (Sivextro; Merck Sharp & Dohme) has been accepted for restricted use and eribulin (Halaven; Eisai) and enzalutamide (Xtandi; Astellas) have not been accepted for use.
Citation: The Pharmaceutical Journal URI: 20069158
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com